Imigran

Sumatriptan, the active ingredient in Imigran, is a Triptan (5‑HT1B/1D receptor agonist) presented as a nasal spray for intranasal use. It is indicated for the acute treatment of migraine attacks in adult patients, providing rapid relief of headache and associated symptoms such as nausea, photophobia, and phonophobia.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across EU and global markets.

Imigran (sumatriptan) is a Triptan used in the migraine pathway to abort acute attacks.

Migraine: provides acute relief of headache and associated symptoms such as nausea, photophobia, and phonophobia.

Common Side Effects: - Taste disturbance: altered or unpleasant taste after administration. - Nasal irritation: burning, stinging, or discomfort in the nasal passages. - Dizziness: sensation of light‑headedness or unsteadiness. - Somnolence: mild sleepiness or fatigue. - Nausea: feeling of queasiness or upset stomach. - Throat irritation: soreness or scratchy feeling in the throat.

Serious or Rare Side Effects: - Coronary vasospasm: chest pain or signs of reduced heart blood flow. - Hypertension: sudden increase in blood pressure. - Serotonin syndrome: agitation, hyperthermia, tremor, and confusion when combined with other serotonergic agents. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Cardiac arrhythmia: irregular heart rhythm. - Ischemic stroke: rare occurrence of cerebrovascular events.

Before using Imigran, consider the following precautions: - Cardiovascular disease: avoid in patients with history of coronary artery disease, myocardial infarction, or uncontrolled angina. - Hypertension: monitor blood pressure and use only if hypertension is well controlled. - Serotonergic agents: assess risk of serotonin syndrome when combined with SSRIs, SNRIs, or MAO inhibitors. - Pregnancy: safety not established; prescribe only if potential benefit justifies potential risk to the fetus. - Pediatric use: not established in children; use only under specialist supervision. - Store at room temperature: keep in original packaging, protect from moisture and direct heat.

Imigran may interact with several medicines. Review the following categories:

Major Interactions (Avoid): - MAO inhibitors: concurrent use can precipitate severe hypertension. - Other triptans or ergot derivatives: increased risk of vasospastic events. - SSRIs, SNRIs, or other serotonergic drugs: heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may enhance blood pressure‑lowering effects. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase sumatriptan plasma levels. - Dihydropyridine calcium‑channel blockers: potential additive cardiovascular effects. - Oral contraceptives: monitor for increased migraine frequency. - NSAIDs: combined use may increase risk of gastrointestinal irritation.